Clinical scale Phase 1b safety and dosing trial in early stage prostate cancer underway with eRapa, plus planned pilot efficacy study for FAP, signaling ongoing clinical development and potential expansion into additional cancer indications.

Strategic licensing Exclusive worldwide license rights secured by Biodexa for eRapa with potential sublicensing, indicating a clear path for collaborative development, manufacturing, and commercialization opportunities.

Non-dilutive support Significant CPRIT funding rounds including a $16.9M grant and a recent $3M grant bring total non-dilutive support to enhance clinical and product development, improving near-term funding stability for partnerships and trials.

Capital readiness Current funding of $17M and modest revenue base position Emtora as an attractive partner for CROs, manufacturers, and distributors seeking innovative oncology formulations with near-term clinical milestones.

Strategic partnerships Past collaborations with industry players and a focused pipeline around encapsulated rapamycin (eRapa) open doors for co-development, manufacturing agreements, and regional access partnerships in oncology and preventative medicine.